This case highlights the potential for early emergence of neuroendocrine differentiation in patients with metastatic castration-sensitive prostate cancer undergoing triplet therapy with androgen deprivation therapy, darolutamide, and docetaxel, even with marked prostate-specific antigen (PSA) suppression. This evidence concerns the gene KLK3 and prostate cancer.